Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse

Completed

• Conditions: Myocardial Infarction
• Interventions: Drug: Metalyse weight-adjusted

• Registration Number: NCT02194153
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical trials.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-05
• Primary Completion: 2003-03
• Status Verified: 2014-07
• Study First Submitted: 2014-07-17
• Study First Submitted QC: 2014-07-17
• Last Update Submitted: 2014-07-17
• Study First Posted: 2014-07-18
• Last Update Posted: 2014-07-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 351

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Metalyse	Metalyse weight-adjusted	Metalyse weight-adjusted

Primary Outcome Measures

Name	Time	Method
Pain relief	90 min, 120 min, up to 30 days after treatment initiation	yes/no question
Complete ST-segment resolution	up to 30 days
Change in creatine kinase (CK)	up to 24 hours
Change in creatine kinase-MB (CK-MB)	up to 24 hours
Change in troponin	up to 24 hours